CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study (vol 13, 44, 2023)

被引：0

作者：

Niu, Jiahua ^{[1
,2
]}

Qiu, Huiying ^{[1
,2
]}

Xiang, Fang ^{[3
]}

Zhu, Lin ^{[3
]}

Yang, Jun ^{[1
,2
]}

Huang, Chongmei ^{[1
,2
]}

Zhou, Kun ^{[1
,2
]}

Tong, Yin ^{[1
,2
]}

Cai, Yu ^{[1
,2
]}

Dong, Baoxia ^{[1
,2
]}

Lu, Yuan ^{[3
]}

Sun, Xuedong ^{[3
]}

Wan, Liping ^{[1
,2
]}

Ding, Xueying ^{[2
]}

Wang, Haopeng ^{[4
]}

Song, Xianmin ^{[1
,2
]}

机构：

[1] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Hematol, Shanghai, Peoples R China

[2] Shanghai Sci & Technol Comm STCSM, Engn Technol Res Ctr Cell Therapy & Clin Translat, Shanghai, Peoples R China

[3] Hrain Biotechnol, Shanghai, Peoples R China

[4] Shanghai Tech Univ, Sch Life Sci & Technol, Shanghai, Peoples R China

来源：

BLOOD CANCER JOURNAL | 2023年 / 13卷 / 01期

基金：

国家重点研发计划;

关键词：

D O I：

10.1038/s41408-023-00825-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：1

共 50 条

[21] Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
Li, Wenjie
Ding, Lixia
Shi, Wenhua
Wan, Xinyu
Yang, Xiaomin
Yang, Jing
Wang, Tianyi
Song, Lili
Wang, Xiang
Ma, Yani
Luo, Chengjuan
Tang, Jingyan
Gu, Longjun
Chen, Jing
Lu, Jun
Tang, Yanjing
Li, Benshang
JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
[22] Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation
Hejin Jia
Zhenguang Wang
Yao Wang
Yang Liu
Hanren Dai
Chuan Tong
Yelei Guo
Bo Guo
Dongdong Ti
Xiao Han
Qingming Yang
Zhiqiang Wu
Weidong Han
Journal of Hematology & Oncology, 12
[23] Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation
Jia, Hejin
Wang, Zhenguang
Wang, Yao
Liu, Yang
Dai, Hanren
Tong, Chuan
Guo, Yelei
Guo, Bo
Ti, Dongdong
Han, Xiao
Yang, Qingming
Wu, Zhiqiang
Han, Weidong
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)
[24] A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
Wang, Yiyun
Yang, Yingying
Hong, Ruimin
Zhao, Houli
Wei, Guoqing
Wu, Wenjun
Xu, Huijun
Cui, Jiazhen
Zhang, Yanlei
Chang, Alex H.
Hu, Yongxian
Huang, He
BLOOD CANCER JOURNAL, 2020, 10 (10)
[25] A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
Yiyun Wang
Yingying Yang
Ruimin Hong
Houli Zhao
Guoqing Wei
Wenjun Wu
Huijun Xu
Jiazhen Cui
Yanlei Zhang
Alex H. Chang
Yongxian Hu
He Huang
Blood Cancer Journal, 10
[26] CAR-T Cell Therapy With CRISPR/CAS9 Engineering for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia, With Universal Dual Target CD19/CD22
Baptista, Gabriel
Carvalho, Julia
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S529 - S529
[27] CD19 and CD22-directed biespecific CAR for B-cell Acute Lymphoblastic Leukemia
Zanetti, S. R.
Velasco-Hernandez, T.
Gutierrez-Aguera, F.
Roca-Ho, H.
Sanchez-Martinez, D.
Petazzi, P.
Torres, R.
Molina, O.
Torrebadell-Burriel, M.
Vidriales-Vicente, M. B.
Hrusak, O.
Fuster, J. L.
Juan, M.
Bueno, C.
Menendez, P.
HUMAN GENE THERAPY, 2019, 30 (11) : A54 - A54
[28] CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
Spiegel, Jay Y.
Patel, Shabnum
Muffly, Lori
Hossain, Nasheed M.
Oak, Jean
Baird, John H.
Frank, Matthew J.
Shiraz, Parveen
Sahaf, Bita
Craig, Juliana
Iglesias, Maria
Younes, Sheren
Natkunam, Yasodha
Ozawa, Michael G.
Yang, Eric
Tamaresis, John
Chinnasamy, Harshini
Ehlinger, Zach
Reynolds, Warren
Lynn, Rachel
Rotiroti, Maria Caterina
Gkitsas, Nikolaos
Arai, Sally
Johnston, Laura
Lowsky, Robert
Majzner, Robbie G.
Meyer, Everett
Negrin, Robert S.
Rezvani, Andrew R.
Sidana, Surbhi
Shizuru, Judith
Weng, Wen-Kai
Mullins, Chelsea
Jacob, Allison
Kirsch, Ilan
Bazzano, Magali
Zhou, Jing
Mackay, Sean
Bornheimer, Scott J.
Schultz, Liora
Ramakrishna, Sneha
Davis, Kara L.
Kong, Katherine A.
Shah, Nirali N.
Qin, Haiying
Fry, Terry
Feldman, Steven
Mackall, Crystal L.
Miklos, David B.
NATURE MEDICINE, 2021, 27 (08) : 1419 - +
[29] CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Hu, Yongxian
Zhou, Yali
Zhang, Mingming
Ge, Wengang
Li, Yi
Yang, Li
Wei, Guoqing
Han, Lu
Wang, Hao
Yu, Shuhui
Chen, Yi
Wang, Yanbin
He, Xiaohong
Zhang, Xingwang
Gao, Ming
Yang, Jingjing
Li, Xiuju
Ren, Jiangtao
Huang, He
CLINICAL CANCER RESEARCH, 2021, 27 (10) : 2764 - 2772
[30] CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
Jay Y. Spiegel
Shabnum Patel
Lori Muffly
Nasheed M. Hossain
Jean Oak
John H. Baird
Matthew J. Frank
Parveen Shiraz
Bita Sahaf
Juliana Craig
Maria Iglesias
Sheren Younes
Yasodha Natkunam
Michael G. Ozawa
Eric Yang
John Tamaresis
Harshini Chinnasamy
Zach Ehlinger
Warren Reynolds
Rachel Lynn
Maria Caterina Rotiroti
Nikolaos Gkitsas
Sally Arai
Laura Johnston
Robert Lowsky
Robbie G. Majzner
Everett Meyer
Robert S. Negrin
Andrew R. Rezvani
Surbhi Sidana
Judith Shizuru
Wen-Kai Weng
Chelsea Mullins
Allison Jacob
Ilan Kirsch
Magali Bazzano
Jing Zhou
Sean Mackay
Scott J. Bornheimer
Liora Schultz
Sneha Ramakrishna
Kara L. Davis
Katherine A. Kong
Nirali N. Shah
Haiying Qin
Terry Fry
Steven Feldman
Crystal L. Mackall
David B. Miklos
Nature Medicine, 2021, 27 : 1419 - 1431

← 1 2 3 4 5 →